The BioPharm Brief: Designations, Decisions, and Data

Jul 29, 08:51 PM
Headliner
Share
Subscribe

Today's episode explores how FDA expedited pathways continue to shape advanced therapy development, from new RMAT designations for cell and gene therapies to an advisory committee review that underscores the agency's evolving expectations for clinical evidence.

Share
Subscribe
Next
The BioPharm Brief: Expansion, Engineering, and Evolution
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief